Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-03-22, Stock:PFE, The news for the past five days is as follows:
2019-03-15: NEWS1: After Hours Most Active for Mar 15, 2019 :  PFE, VSTM, ZNGA, GE, CSCO, KO, WFC, DO, MSFT, BAC, INTC, HBAN.NEWS2: After Hours Most Active for Mar 15, 2019 :  PFE, VSTM, ZNGA, GE, CSCO, KO, WFC, DO, MSFT, BAC, INTC, HBAN.NEWS3: Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others.NEWS4: Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others.NEWS5: Notable ETF Inflow Detected - SPYG, PFE, BRK.B, PYPL.NEWS6: Notable ETF Inflow Detected - SPYG, PFE, BRK.B, PYPL.NEWS7: Dow 30 Stock Roundup: PFE's Herceptin Biosimilar Gets FDA Nod, VZ to Launch 5G Soon.NEWS8: Dow 30 Stock Roundup: PFE's Herceptin Biosimilar Gets FDA Nod, VZ to Launch 5G Soon.NEWS9: The Case Against Pfizer Stock and the Rest of the Industry.NEWS10: Pisani: S&P rebalancing as some companies aggressively buy back stock.NEWS11: Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others.NEWS12: Dow 30 Stock Roundup: PFE's Herceptin Biosimilar Gets FDA Nod, VZ to Launch 5G Soon.NEWS13: The Case Against Pfizer Stock and the Rest of the Industry.
2019-03-18: NEWS1: Bristol-Myers & Pfizer Release Phase IV Data on Eliquis.NEWS2: Big Pharma Earnings Might Not Be as Good as They Look.NEWS3: UnitedHealth Shares Finding Their Mojo Again.NEWS4: The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J.NEWS5: The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J.NEWS6: Group with consumer-friendly vibe pushes drugmakers' message.NEWS7: The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J.NEWS8: Outside political groups not always what they appear.
2019-03-19: NEWS1: Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer.NEWS2: Dow Snaps Win Streak on U.S.-China Trade Concerns.NEWS3: Dow Snaps Win Streak on U.S.-China Trade Concerns.NEWS4: Pfizer (PFE) Gains As Market Dips: What You Should Know.NEWS5: After Hours Most Active for Mar 19, 2019 :  TFCFA, TFCF, LLY, BRX, TWTR, BAC, PFE, EBAY, S, MSFT, CMCSA, INTC.NEWS6: After Hours Most Active for Mar 19, 2019 :  TFCFA, TFCF, LLY, BRX, TWTR, BAC, PFE, EBAY, S, MSFT, CMCSA, INTC.NEWS7: Market Close Report: NASDAQ Composite index closes at 7,723.95 up 9.47 points.NEWS8: Market Close Report: NASDAQ Composite index closes at 7,723.95 up 9.47 points.NEWS9: Analysts Reduce Pfizer’s Target Price in March.NEWS10: Why You Should Buy ABBV Stock for Income and Value.NEWS11: Why You Should Buy ABBV Stock for Income and Value.NEWS12: Allergan's Anti-Infective Gets FDA Nod for Pediatric Patients.NEWS13: Allergan's Anti-Infective Gets FDA Nod for Pediatric Patients.NEWS14: Aerie (AERI) Starts Phase II Study on Eye Candidate AR-1105.NEWS15: Aerie (AERI) Starts Phase II Study on Eye Candidate AR-1105.NEWS16: Aerie (AERI) Starts Phase II Study on Eye Candidate AR-1105.NEWS17: 3 Stocks to Build Your Portfolio Around.NEWS18: 3 Stocks to Build Your Portfolio Around.NEWS19: Allergan's Anti-Infective Gets FDA Nod for Pediatric Patients.NEWS20: 3 Stocks to Build Your Portfolio Around.NEWS21: Why You Should Buy ABBV Stock for Income and Value.NEWS22: Pfizer Invites Public to View and Listen to Webcast of April 30 Conference Call with Analysts.NEWS23: Health Care Sector Update for 03/19/2019: TYHT, ALT, AQB, JNJ, PFE, MRK, ABT, AMGN.NEWS24: Health Care Sector Update for 03/19/2019: TYHT, ALT, AQB, JNJ, PFE, MRK, ABT, AMGN.NEWS25: Bristol-Myers & Pfizer Release Phase IV Data on Eliquis.NEWS26: Bristol-Myers & Pfizer Release Phase IV Data on Eliquis.
2019-03-20: NEWS1: After Hours Most Active for Mar 20, 2019 :  NLY, XOG, GE, MCHI, ELAN, T, QQQ, MU, NWL, AMD, PFE, DIS.NEWS2: After Hours Most Active for Mar 20, 2019 :  NLY, XOG, GE, MCHI, ELAN, T, QQQ, MU, NWL, AMD, PFE, DIS.NEWS3: Invest in America’s Rising Healthcare Costs With These Stocks.NEWS4: Pfizer buys stake in French gene therapy firm Vivet.NEWS5: Glaxo Presents Encouraging Data on Endometrial Cancer Drug.NEWS6: Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan.NEWS7: Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan.NEWS8: Pfizer/Merck KGaA End Bavencio+Talzenna Ovarian Cancer Study.NEWS9: Pfizer/Merck KGaA End Bavencio+Talzenna Ovarian Cancer Study.NEWS10: Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan.NEWS11: Glaxo Presents Encouraging Data on Endometrial Cancer Drug.NEWS12: Pfizer Acquires Gene Therapy Portfolio in Deal that Could Total $636 Million.NEWS13: Pfizer Adds to Big Pharma's Gene-Therapy Deal Streak.NEWS14: The Daily Biotech Pulse: FDA Nod For Sage's Postpartum Depression Drug, Pfizer Invests In Gene Therapy Company.NEWS15: Pfizer acquires option to buy Vivet Therapeutics for equivalent of $635.8 million.NEWS16: Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics.NEWS17: 5 High-Quality, High-Yielding Stocks.NEWS18: Stocks -  FedEx, Google Fall in Pre-market; General Mills Jumps.NEWS19: Pfizer (PFE) Gains As Market Dips: What You Should Know.NEWS20: Pfizer (PFE) Gains As Market Dips: What You Should Know.
2019-03-21: NEWS1: Biogen’s Big Bet in Alzheimer’s Disease Is a Bust.NEWS2: Biogen’s Big Bet in Alzheimer’s Disease Is a Bust.NEWS3: Boeing&apos;s Lesson About The Dow.NEWS4: Merck's Keytruda Picks Up Pace in Thriving Anti-PD-L1 Market.NEWS5: Merck's Keytruda Picks Up Pace in Thriving Anti-PD-L1 Market.NEWS6: Merck's Keytruda Picks Up Pace in Thriving Anti-PD-L1 Market.NEWS7: Pfizer buys stake in French gene company in deal worth up to $636M.NEWS8: Health Care Sector Update for 03/21/2019: BIIB, OGEN, NVCN, JNJ, PFE, ABT, MRK, AMGN.NEWS9: Health Care Sector Update for 03/21/2019: BIIB, OGEN, NVCN, JNJ, PFE, ABT, MRK, AMGN.NEWS10: Novo Nordisk A/S (NVO) Ex-Dividend Date Scheduled for March 22, 2019.NEWS11: Novo Nordisk A/S (NVO) Ex-Dividend Date Scheduled for March 22, 2019.NEWS12: 5 of the Best Dow Jones Stocks to Buy for Solid Dividends.NEWS13: 5 of the Best Dow Jones Stocks to Buy for Solid Dividends.

Answer: Decrease